Ionis to present at upcoming investor conferences
Get Alerts IONS Hot Sheet
Join SI Premium – FREE
- Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference on
Tuesday, November 7, 2023 - Stifel 2023 Healthcare Conference on
Tuesday, November 14, 2023 - Piper Sandler 35th Annual Healthcare Conference 2023 on
Tuesday, November 28, 2023 - BMO 2023 Growth & ESG Conference on
Monday, December 4, 2023
A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-301976539.html
SOURCE Ionis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Heavy Rains Cause Temporary Discharge of Partially Treated Wastewater at Sandy Beach
- Family Files Lawsuit Against Cody Casey in Fatal Fourth of July Herrington Lake Boat Collision
- Glodon Launches QuantifAI in Malaysia at AEC Connect Day 2026, Advancing AI-Powered Quantity Takeoff
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Stifel, Twitter, GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share